AARTI PHARMALABS LIMITED (AARTIPHARM) financials

AARTI PHARMALABS LIMITED (AARTIPHARM) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals[1]

Market Cap: ₹7,922Cr.
Current Price: ₹874
Stock P/E: 37.7
ROE: 9.32%
ROCE: 11.4%
Book Value: ₹219
Dividend Yield: 0.40%
52W High / Low: ₹1,002/584

In Jun 2026, AARTI PHARMALABS LIMITED (AARTIPHARM) reported sales ₹535 Cr and net profit ₹71 Cr.

Annual TTM: sales ₹1,957 Cr, net profit ₹208 Cr.

Shareholding: Promoters 42.86% (Jun 2026), FIIs 8.17% (Jun 2026), DIIs 7.22% (Jun 2026), Government 0.01% (Jun 2026), Public 41.74% (Jun 2026).

AARTIPHARM quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	377	471	530	375	417	425	580	535
Expenses	293	356	386	280	343	322	463	398
Operating Profit	85	115	143	95	74	103	117	136
OPM %	22%	24%	27%	25%	18%	24%	20%	25%
Other Income	3	12	-3	2	3	-3	11	3
Interest	5	10	6	7	11	13	17	13
Depreciation	19	21	21	23	25	29	28	30
Profit before tax	63	96	114	67	42	59	83	96
Tax %	25%	24%	22%	24%	26%	25%	25%	26%
Net Profit	48	74	89	51	31	44	62	71
EPS in Rs	5.28	8.11	9.80	5.65	3.41	4.84	6.84	7.86
Raw PDF	—	—	—	—	—	—	—	—

AARTIPHARM profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	0	0	941	1,511	1,502	1,771	1,798	1,957
Expenses	0	0	761	1,203	1,156	1,343	1,425	1,527
Operating Profit	-0	0	180	308	346	428	373	430
OPM %	—	—	19%	20%	23%	24%	21%	22%
Other Income	0	0	3	1	11	13	13	13
Interest	0	0	11	20	17	26	47	53
Depreciation	0	0	37	56	66	79	104	112
Profit before tax	-0	0	134	233	275	336	234	279
Tax %	0%	—	20%	26%	27%	23%	25%	—
Net Profit	-0	0	107	172	201	257	176	208
EPS in Rs	—	—	—	18.95	22.14	28.39	19.44	22.95
Dividend Payout %	0%	—	0%	11%	14%	18%	18%	—

AARTIPHARM balance sheet (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	0.25	0.25	0.25	45	45	45	45
Reserves	-0	-0	1,284	1,393	1,576	1,799	1,937
Borrowings	0	0	327	208	272	411	754
Other Liabilities	0	0	215	330	404	464	591
Total Liabilities	0	0	1,827	1,976	2,297	2,720	3,328
Fixed Assets	0	0	701	848	953	1,059	1,437
CWIP	0	0	187	102	137	369	393
Investments	0	0	40	55	62	57	44
Other Assets	0	0	898	971	1,145	1,235	1,453
Total Assets	0	0	1,827	1,976	2,297	2,720	3,328

AARTIPHARM cash flows (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	-0	0	-65	216	184	339	257
Cash from Investing Activity	0	0	-134	-116	-184	-418	-425
Cash from Financing Activity	0	0	255	-157	4	79	171
Net Cash Flow	0	0	56	-56	4	-1	3
Free Cash Flow	-0	0	-201	99	-5	-95	-191
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	100%	—	-28%	88%	67%	93%	82%

AARTIPHARM shareholding pattern (%)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Promoters	46.10%	44.65%	44.29%	43.72%	42.88%	43.10%	43.08%	42.86%
FIIs	7.38%	8.64%	7.36%	7.34%	8.02%	7.69%	8.39%	8.17%
DIIs	11.35%	10.36%	7.53%	7.80%	6.95%	7.66%	7.40%	7.22%
Government	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%
Public	35.17%	36.33%	40.81%	41.12%	42.12%	41.54%	41.10%	41.74%
No. of Shareholders	1,85,436	1,85,111	1,96,314	1,87,039	1,90,655	1,84,489	1,79,373	1,76,506

AARTIPHARM key ratios
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	—	—	118	90	109	114	119
Inventory Days	—	—	359	240	283	239	283
Days Payable	—	—	106	95	124	109	144
Cash Conversion Cycle	—	—	371	235	268	243	258
Working Capital Days	—	—	137	118	135	118	94
ROCE %	—	0%	18%	16%	16%	17%	11%

AARTIPHARMUpdated 18 Oct 2026, 0:59

Aarti Pharmalabs Limited

AARTIPHARMUpdated 18 Oct 2026, 0:59

Market Cap

₹7,922Cr.

Current Price

₹874

High / Low

₹1,002/584

Stock P/E

37.7

ROE9.32%

ROCE11.4%

Book Value₹219

Face Value₹5.00

Dividend Yield0.40%

About

Incorporated in 2019, Aarti Pharmalabs Ltd is a manufacturer of Pharmaceuticals and Nutraceuticals[1]

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	358	4	281	5	15	62	23	48	5.26
Sep 2023	356	4	282	0	16	54	22	42	4.61
Dec 2023	373	4	285	0	17	67	29	48	5.32
Mar 2024	415	4	307	6	17	91	31	63	6.95
Jun 2024	393	4	310	2	18	63	25	47	5.2
Sep 2024	377	5	293	3	19	63	25	48	5.28
Dec 2024	471	10	356	12	21	96	24	74	8.11
Mar 2025	530	6	386	-3	21	114	22	89	9.8
Jun 2025	375	7	280	2	23	67	24	51	5.65
Sep 2025	417	11	343	3	25	42	26	31	3.41
Dec 2025	425	13	322	-3	29	59	25	44	4.84
Mar 2026	580	17	463	11	28	83	25	62	6.84
Jun 2026	535	13	398	3	30	96	26	71	7.86

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2020	0	0	0	0	0	0	0	0	—
Mar 2021	0	0	0	0	0	0	—	0	—
Mar 2022	941	11	761	3	37	134	20	107	—
Mar 2023	1511	20	1203	1	56	233	26	172	18.95
Mar 2024	1502	17	1156	11	66	275	27	201	22.14
Mar 2025	1771	26	1343	13	79	336	23	257	28.39
Mar 2026	1798	47	1425	13	104	234	25	176	19.44
TTM	1957	53	1527	13	112	279	—	208	22.95

Shareholding pattern

As of Jun 2026%

Holder	Share
Promoters	42.86%
FIIs	8.17%
DIIs	7.22%
Government	0.01%
Public	41.74%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Government	Public
Sep 2023	46.3%	8.45%	10.51%	0.01%	34.73%
Dec 2023	46.46%	8.17%	9.91%	0.01%	35.45%
Mar 2024	46.46%	8.33%	9.97%	0.01%	35.24%
Jun 2024	46.46%	7.07%	11.47%	0.01%	35%
Sep 2024	46.1%	7.38%	11.35%	0.01%	35.17%
Dec 2024	44.65%	8.64%	10.36%	0.01%	36.33%
Mar 2025	44.29%	7.36%	7.53%	0.01%	40.81%
Jun 2025	43.72%	7.34%	7.8%	0.01%	41.12%
Sep 2025	42.88%	8.02%	6.95%	0.01%	42.12%
Dec 2025	43.1%	7.69%	7.66%	0.01%	41.54%
Mar 2026	43.08%	8.39%	7.4%	0.01%	41.1%
Jun 2026	42.86%	8.17%	7.22%	0.01%	41.74%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2020	0.25	0	0	0	0	0	0	0	0	0
Mar 2021	0.25	0	0	0	0	0	0	0	0	0
Mar 2022	0.25	1284	327	215	1827	701	187	40	898	1827
Mar 2023	45	1393	208	330	1976	848	102	55	971	1976
Mar 2024	45	1576	272	404	2297	953	137	62	1145	2297
Mar 2025	45	1799	411	464	2720	1059	369	57	1235	2720
Mar 2026	45	1937	754	591	3328	1437	393	44	1453	3328

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2020	0	0	0	0
Mar 2021	0	0	0	0
Mar 2022	-65	-134	255	56
Mar 2023	216	-116	-157	-56
Mar 2024	184	-184	4	4
Mar 2025	339	-418	79	-1
Mar 2026	257	-425	171	3

Key ratios

Historical financial ratios

Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	—	—	118	90	109	114	119
Inventory Days	—	—	359	240	283	239	283
Days Payable	—	—	106	95	124	109	144
Cash Conversion Cycle	—	—	371	235	268	243	258
Working Capital Days	—	—	137	118	135	118	94
ROCE %	—	0%	18%	16%	16%	17%	11%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of AARTI PHARMALABS LIMITED (AARTIPHARM)?

The reported market capitalisation for AARTI PHARMALABS LIMITED (AARTIPHARM) is ₹7,922Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of AARTIPHARM?

The current price shown for AARTI PHARMALABS LIMITED (AARTIPHARM) on Fincrux is ₹874 with a 52-week high/low of ₹1,002/584.

What is the P/E ratio of AARTI PHARMALABS LIMITED (AARTIPHARM)?

The stock P/E for AARTI PHARMALABS LIMITED (AARTIPHARM) is 37.7 on Fincrux, with ROE at 9.32% and ROCE at 11.4%.

What were AARTIPHARM latest quarterly results?

For Jun 2026, AARTI PHARMALABS LIMITED (AARTIPHARM) reported sales ₹535 Cr and net profit ₹71 Cr (figures in ₹ crore unless noted).

What are AARTIPHARM annual sales and net profit?

For TTM, AARTI PHARMALABS LIMITED (AARTIPHARM) shows sales of ₹1,957 Cr and net profit of ₹208 Cr on the Fincrux profit & loss statement.

Who owns AARTI PHARMALABS LIMITED (AARTIPHARM)?

Latest shareholding for AARTI PHARMALABS LIMITED (AARTIPHARM) on Fincrux: Promoters 42.86% (Jun 2026), FIIs 8.17% (Jun 2026), DIIs 7.22% (Jun 2026), Government 0.01% (Jun 2026), Public 41.74% (Jun 2026).

Where can I find AARTI PHARMALABS LIMITED (AARTIPHARM) financials?

AARTI PHARMALABS LIMITED (AARTIPHARM) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show AARTIPHARM balance sheet and cash flow?

Yes. The AARTI PHARMALABS LIMITED (AARTIPHARM) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 18 October 2026 at 0:59